HAVN Life Sciences Inc. (HAVLF)
HAVN Life Sciences Inc. is a biotechnology firm that specializes in the research and innovation of psychotropic compounds derived from botanical and fungal organisms. The company is also dedicated to establishing standardized, quality-controlled methodologies for extracting these psychoactive molecules, with a specific focus on Psilocybe mushroom species and their key constituents such as psilocybin, psilocin, and baeocystin. Furthermore, it develops natural health products utilizing unregulated ingredients. Founded in 2020, HAVN Life Sciences' operations are headquartered in Richmond, Canada.
Sector: Biotechnology
Industry: Biotechnology
HAVN Life Sciences Inc.
OTC:HAVLFHealthcare · Biotechnology
CLOSED
Mkt Cap-
EV-
Float23.1M
O/S25.65M
VOL116 sh
RVOL1.00×
Inst Own-
Net Cash/Sh+$0.02
Dilution
MCap-Float23.1MO/S25.65M
Dilution
Financials Summary
Revenue$194K
Net Income-$15.71M
Total Assets$2.84M
Free Cash Flow-$5.58M
Debt & Equity
Debt 11%
Equity 89%
Total Debt$273K
Total Equity$2.2M
Shares Outstanding
Short Interest
Split History1 split · 1 reverse
- 1:30Reverse splitAug 3, 202230 shares → 1
Balance Sheet Details
Assets$2.84M
Liabilities$643K
Accounts Receivable$106K
Accounts Payable$225K
Inventory$804K
PP&E (Net)$249K
Goodwill$0
Intangible Assets$654K
Income Statement
| Period | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|
| Currency | USD | USD | USD |
| Period Ending | 2022-04-30 | 2021-04-30 | 2020-04-30 |
| Revenue | $194K | $0 | $0 |
| YoY Growth | - | - | - |
| Cost of Revenue | $131K | $3.22M | $0 |
| Gross Profit | $63K | -$3.22M | $0 |
| Gross Margin | 32.4% | - | - |
| Research and Development | $459K | $233K | $0 |
| Selling, General, and Administrative | $6.07M | $13.59M | $29K |
| Other | $403K | $3.22M | $0 |
| Total Operating Expenses | $6.93M | $17.04M | $29K |
| Operating Income (EBIT) | -$6.87M | -$21.25M | -$28K |
| Operating Margin | -3548.4% | - | - |
| Interest Expense | $45K | $12K | $0 |
| Interest Income | $21K | $0 | $384 |
| Other Income (Expense) | -$8.84M | -$19K | $0 |
| Income Before Tax (EBT) | -$15.71M | -$21.27M | -$28K |
| Income Tax Expense | $0 | $0 | -$144K |
| Net Income | -$15.71M | -$21.27M | -$28K |
| Net Income Margin | -8117.8% | - | - |
| Supplementary Data | |||
| EPS | -5.25 | -8.47 | -0.02 |
| Diluted EPS | -5.25 | -8.47 | -0.02 |
| Weighted Average OS | 4.28M | 3.59M | 2.23M |
| EBITDA | -$5.18M | -$10.39M | $0 |
| EBITDA Margin | -2677.3% | - | - |
Balance Sheet
| Period | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|
| Currency | USD | USD | USD |
| Period Ending | 2022-04-30 | 2021-04-30 | 2020-04-30 |
| Assets | |||
| Current Assets | |||
| Cash and Cash Equivalents | $739K | $6.58M | $1.13M |
| Short-Term Investments | $0 | $0 | $0 |
| Cash and Short-Term Investments | $739K | $6.58M | $1.13M |
| Accounts Receivable | $106K | $147K | $0 |
| Inventory | $804K | $252K | -$175K |
| Other Current Assets | $118K | $0 | $351K |
| Total Current Assets | $1.92M | $7.43M | $1.36M |
| Long-Term Assets | |||
| Property, Plant & Equipment Net | $249K | $477K | $0 |
| Goodwill | $0 | $0 | $0 |
| Intangible Assets | $654K | $2.05M | $0 |
| Long-Term Investments | $0 | $0 | $0 |
| Deferred Tax Assets | $0 | $0 | $0 |
| Other Long-Term Assets | $17K | $13K | $0 |
| Total Long-Term Assets | $920K | $2.54M | $0 |
| Other Assets | $0 | $0 | $0 |
| Total Assets | $2.84M | $9.97M | $1.36M |
| Liabilities | |||
| Current Liabilities | |||
| Accounts Payable | $225K | $374K | $29K |
| Short-Term Debt | $0 | $0 | $0 |
| Current Income Tax Payable | $0 | $0 | $0 |
| Current Unearned Revenue | $0 | $0 | $0 |
| Other Current Liabilities | $99K | $0 | $0 |
| Total Current Liabilities | $426K | $500K | $29K |
| Long-Term Liabilities | |||
| Long-Term Debt | $0 | $0 | $0 |
| Long-Term Unearned Revenue | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 |
| Other Long-Term Liabilities | $0 | $0 | $0 |
| Total Long-Term Liabilities | $217K | $228K | $0 |
| Other Liabilities | $0 | $0 | $0 |
| Total Liabilities | $643K | $728K | $29K |
| Stockholders' Equity | |||
| Preferred Stock | $0 | $0 | $0 |
| Common Stock | $34.41M | $25.9M | $1.35M |
| Retained Earnings | -$37.01M | -$21.3M | -$28K |
| Comprehensive Income & Other | $4.39M | $4.28M | $14K |
| Other Stockholders' Equity | $4.8M | $4.64M | $14K |
| Total Equity | $2.2M | $9.24M | $1.33M |
| Minority Interest | $0 | $0 | $0 |
| Total Liabilities and Equity | $2.84M | $9.97M | $1.36M |
| Supplementary Data | |||
| Total Debt | $273K | $319K | $0 |
| Net Debt | -$466K | -$6.26M | -$1.13M |
Cash Flow Statement
| Period | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|
| Currency | USD | USD | USD |
| Period Ending | 2022-04-30 | 2021-04-30 | 2020-04-30 |
| Operating Activities | |||
| Net Income | -$15.71M | -$21.27M | -$28K |
| Depreciation & Amortization | $403K | $3.22M | $345K |
| Deferred Income Tax | $8.8M | $0 | $0 |
| Stock-Based Compensation | $1.25M | $6.4M | $0 |
| Changes in Working Capital: | |||
| Accounts Receivable | -$76K | -$145K | $0 |
| Inventory | $0 | $0 | $0 |
| Accounts Payable | $0 | $0 | $0 |
| Other Working Capital | -$299K | -$286K | -$630 |
| Total Working Capital Change | -$375K | -$431K | -$24K |
| Other Non-Cash Items | $118K | $4.78M | -$346K |
| Net Cash from Operating | -$5.51M | -$7.3M | -$53K |
| Investing Activities | |||
| Capital Expenditures | -$72K | -$23K | $0 |
| Acquisitions | -$840K | -$242K | $0 |
| Purchases of Investments | $0 | $0 | $0 |
| Sales of Investments | $0 | $0 | $0 |
| Other Investing Activities | -$509K | -$13K | -$175K |
| Net Cash from Investing | -$1.42M | -$278K | -$175K |
| Financing Activities | |||
| Debt Repaid | $92K | $23K | - |
| Common Stock Issuance | $1.4M | $9.89M | $1.35M |
| Common Stock Repurchases | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 |
| Other Financing Activities | -$216K | $3.15M | $14K |
| Net Cash from Financing | $1.09M | $13.02M | $1.36M |
| Forex Effect | $0 | $0 | $0 |
| Net Change in Cash | -$5.84M | $5.45M | $1.13M |
| Supplementary Data | |||
| Operating Cash Flow | -$5.51M | -$7.3M | -$53K |
| Capital Expenditure | -$72K | -$23K | $0 |
| Free Cash Flow | -$5.58M | -$7.32M | -$53K |
| Cash at Beginning | $6.58M | $1.13M | -$63 |
| Cash at End | $739K | $6.58M | $1.13M |